Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Details

for $71 per share in cash, totaling an equity value of approximately $3.7 billion. The acquisition, expected to close in the first half of 2024, will expand Boston Scientific's urology portfolio with Axonics' technologies for treating urinary and bowel dysfunction. The transaction is not expected to significantly impact Boston Scientific's adjusted earnings per share in 2024 but will be accretive thereafter.

Items reported

Exhibits (2)

About Boston Scientific Corporation

Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.